Table 3. Factors associated with SVR12.
| SVR12 (n = 108) | Non-SVR12 (n = 2) | p-value | |
|---|---|---|---|
| Age (yrs) | 65.7±10.4 | 61.2±7.4 | 0.509 |
| Male gender, n (%) | 62 (57) | 1 (50) | 1.000 |
| Prior IFN, n (%) | 62 (57) | 2 (100) | 0.509 |
| Cirrhosis, n (%) | 73 (68) | 2 (100) | 1.000 |
| HCC, n (%) | 11 (10) | 0 (0) | 1.000 |
| AST (U/L) | 87±52 | 55±4 | 0.381 |
| ALT (U/L) | 85±82 | 37±7 | 0.416 |
| Platelet (103/μL) | 133±49 | 151±27 | 0.353 |
| FIB-4 | 4.8±3.2 | 3.3±1.4 | 0.502 |
| Genotype 1a/1b | 4/104 | 0/2 | 1.000 |
| Log HCV RNA (IU/mL) | 5.9±0.9 | 6.8±0.0 | 0.057 |
| Log HCV Ag (fmol/L) | 3.4±0.8 | 4.4±0.5 | 0.056 |
Abbreviation: SVR12, sustained virological response12 weeks off therapy; IFN, interferon; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis index based on 4 factors; HCV, hepatitis C virus